Vaccinex Inc (VCNX) |
|
3.97 -0.25 (-5.92%)
|
02-25 11:41 |
|
Open: |
4.1 |
Pre. Close: |
4.22 |
|
High:
|
4.21 |
Low:
|
3.8 |
|
Volume:
|
1,408,404 |
Market Cap:
|
89M |
|
|
|
|
Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The company is headquartered in Rochester, New York and currently employs 44 full-time employees. The firm is focused on providing treatments for serious diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The company provides SEMA4D antibody platform, which is focused on developing its lead product candidate VX15/2503 (VX15) for the treatment of non-small cell lung cancer, NSCLC, osteosarcoma, melanoma and Huntington’s disease. The company also provides ActiveMAb antibody discovery platform, a human antibody discovery platform used for expressing large and diverse libraries of high affinity, full-length human monoclonal antibodies on the surface of vaccinia, a mammalian virus. Its product candidate VX5 is in preclinical development for the treatment of multiple sclerosis and potentially for other autoimmune disorders. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
4.633 - 4.655 |
4.655 - 4.676 |
|
Low:
|
3.97 - 3.992 |
3.992 - 4.014 |
|
Close:
|
4.182 - 4.218 |
4.218 - 4.253 |
|
Technical analysis |
as of: 2021-02-25 11:18:17 AM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 7.93 One year: 11.17 |
| Support: |
Support1: 2.30 Support2: 1.91 |
| Resistance: |
Resistance1: 6.79 Resistance2: 9.56 |
| Pivot: |
3.58  |
| Moving Average: |
MA(5): 4.44 MA(20): 3.34
MA(100): 2.34 MA(250): 3.60 |
| MACD: |
MACD(12,26): 0.44 Signal(9): 0.36 |
| Stochastic oscillator: |
%K(14,3): 20.55 %D(3): 26.55 |
| RSI: |
RSI(14): 58.32 |
| 52-week: |
High: 9.56 Low: 1.63 Change(%): -25.6 |
| Average Vol(K): |
3-Month: 555281 10-Days: 3032053 |
|
Price, moving averages and Bollinger Bands |
|
Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.VCNX has closed below upper band by 35.2%. Bollinger Bands are 159.7% wider than normal. The large width of the bands suggest high volatility as compared to VCNX's normal range. The bands have been in this wide range for 4 bars. This is a sign that the current trend might continue. |
|
|
Headline News |
Wed, 24 Feb 2021
Should Biotechnology Stock Vaccinex Inc (VCNX) Be in Your Portfolio Wednesday? - InvestorsObserver
Tue, 23 Feb 2021
Premarket Mover: Vaccinex Inc (VCNX) Down 11.94% - InvestorsObserver
Mon, 22 Feb 2021
Vaccinex Announces Licensing of Anti-CCR8 Antibody to Surface Oncology - GlobeNewswire
Fri, 19 Feb 2021
Mid-afternoon market update: S&P 500 turns negative; Vaccinex (VCNX Stock) shares spike higher - FXStreet
Fri, 19 Feb 2021
Do Traders View Vaccinex Inc (VCNX) Stock's Current Trend Positively? - InvestorsObserver
Fri, 19 Feb 2021
VCNX Stock: 11 Things to Know About Vaccinex and the Deals That Have Shares Soaring - InvestorPlace
|
Financial Analysis |
| Growth |
n/a |
| Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing. |
| Profitability |
n/a |
| Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs. |
| Solvency |
n/a |
| Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry. |
| Efficiency |
n/a |
| Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not. |
| Price to Book Value: |
Underperform |
Discounted cash flow: |
Outperform |
| Return on Assets: |
Underperform |
Price to Earnings: |
Underperform |
| Return on Equity: |
Outperform |
Debt to Equity: |
Underperform |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. (M) |
22 |
| Shares Float (M) |
9 |
|
% Held by Insiders
|
18.40 |
|
% Held by Institutions
|
50.40 |
|
Shares Short (K)
|
177 |
|
Shares Short P. Month (K)
|
257 |
Stock Financials |
|
EPS
|
-1.702 |
|
EPS Est This Year
|
|
|
EPS Est Next Year
|
|
|
Book Value (p.s.)
|
-0.900 |
|
Profit Margin
|
|
|
Operating Margin
|
-4572.96 |
|
Return on Assets (ttm)
|
-121.0 |
|
Return on Equity (ttm)
|
-748.4 |
|
Qtrly Rev. Growth
|
54.7 |
|
Gross Profit (p.s.)
|
0.014 |
|
Sales Per Share
|
0.028 |
|
EBITDA (p.s.)
|
-1.263 |
|
Qtrly Earnings Growth
|
|
|
Operating Cash Flow (M)
|
-28 |
|
Levered Free Cash Flow (M)
|
-18 |
Stock Valuations |
|
PE Ratio
|
-2.34 |
|
PEG Ratio
|
|
|
Price to Book value
|
-4.42 |
|
Price to Sales
|
142.58 |
|
Price to Cash Flow
|
-3.17 |
Stock Dividends |
|
Dividend
|
|
|
Forward Dividend
|
|
|
Dividend Yield
|
|
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
